Filter

41 - 50 of 351 Results

  • Mixed Prospects for Vaccinating Children

    From Drew Altman

    In this Axios column, Drew Altman examines the data about what parents say they will do once their children ages 5-11 become eligible for a COVID-19 vaccine, and why it will take some time and a concerted outreach effort to match adult vaccination rates.

  • Where To Start To Build Vaccine Confidence

    From Drew Altman

    In this Axios column Drew Altman writes about the recent attention to Republican vaccine resisters. “Republicans and rural Americans are among the most resistant vaccine holdouts and some strategies are emerging to reach them." But “far from all Republicans are resisters” and “the bigger and quicker payoff will come from prioritizing the more moveable group of 'wait and see' Americans.”

  • The Sad State of Trust in the CDC and FDA

    From Drew Altman

    In his latest column, KFF’s President and CEO Drew Altman discusses how the low levels of trust in the CDC and FDA today seen in KFF’s recent survey findings present a danger should the country face another epidemic.

  • Do We Want to Outsource U.S. Vaccine Policy to Denmark?

    Quick Take

    Adopting Denmark’s vaccine schedule, as HHS Secretary Kennedy's vaccine advisors have suggested, would likely lower childhood vaccination rates in the U.S. as certain vaccines become harder to access.

  • Vaccine Misinformation Spreads as Children Head Back to School — The Monitor

    Feature

    This edition highlights vaccine hesitancy and misinformation around MMR (measles, mumps, and rubella) vaccines as children return to school and measles cases resurge in parts of the U.S. It also examines emerging narratives around COVID-19 vaccine misinformation following the FDA approval of COVID-19 boosters and false claims linking mpox to the vaccines.